

The clinical and cost effectiveness of of a steroid injection versus a night splint for Carpal Tunnel Syndrome

Submission date 01/05/2014	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 01/05/2014	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 26/03/2019	Condition category Nervous System Diseases	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Carpal Tunnel Syndrome (CTS) is a common condition in which a nerve (known as the median nerve) is squeezed where it passes through the wrist. It can cause pain or aching, tingling or numbness in the affected hand. It may disturb sleep, or affect ability to do day to day things. There have been several studies into the best treatment of patients with severe symptoms of CTS who are referred to a hospital for treatment. However, little is known about the best treatments for patients with mild to moderate symptoms who visit their GP but do not require hospital treatment. This study aims to find out whether a single steroid injection is effective in treating CTS symptoms when compared with a night splint in people suffering with mild to moderate carpal tunnel syndrome.

Who can participate?

Patients aged 18 and over who have been diagnosed with mild to moderate CTS which has been present for at least 6 weeks

What does the study involve?

Each participant is randomly allocated to receive either a single steroid injection or a splint, and is asked to complete up to five questionnaires over 2 years. The steroid is a drug called DepoMedrone and is already widely used to treat CTS. The splint is made of elastic and has an aluminium bar which sits on the palm of the hand. In this study, the splint will be worn at night for 6 weeks. We study the effects of these two treatments over 6 weeks and at 6 months. We also look at whether these 6 weeks of treatment are effective 1 year and 2 years later.

What are the possible benefits and risks of participating?

Not provided at time of registration

Where is the study run from?

The study will take place in up to 50 GP practices and hospital clinics across the UK

When is the study starting and how long is it expected to run for?
April 2014 to September 2017

Who is funding the study?
Arthritis Research UK

Who is the main contact?
Jacqueline Gray
j.gray@keele.ac.uk

Contact information

Type(s)
Scientific

Contact name
Ms Jacqueline Gray

Contact details
Arthritis Research UK Primary Care Centre
Primary Care Sciences
Keele University
Newcastle-Under-Lyme
United Kingdom
ST5 5BG
-
j.gray@keele.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)
2013-001435-48

ClinicalTrials.gov (NCT)
NCT02038452

Protocol serial number
16390

Study information

Scientific Title
The clinical and cost effectiveness of of a steroid injection versus a night splint for Carpal Tunnel Syndrome: a pragmatic randomised trial in primary care

Acronym
INjection versus SplinTing in Carpal Tunnel Syndrome (INSTinCTS)

Study objectives

The study aims to find out whether a single steroid injection is effective in treating CTS symptoms when compared with a night splint in people suffering with mild to moderate carpal tunnel syndrome.

Ethics approval required

Old ethics approval format

Ethics approval(s)

13/NW/0280; First MREC approval date 07/05/2013

Study design

Randomised; Interventional; Design type: Treatment

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Topic: Primary Care, Musculoskeletal disorders; Subtopic: Not Assigned, Musculoskeletal (all Subtopics); Disease: All Diseases, Musculoskeletal Pain Disorders

Interventions

Each participant will receive either a single steroid injection or a splint. The steroid is a drug called DepoMedrone 20mg. This drug is already widely used to treat CTS. In this study, one injection will be given. The splint is made of elastic and has an aluminium bar which sits on the palm of the hand. In this study, the splint will be worn at night for 6 weeks. Each participant will be asked to complete up to 5 questionnaires over 2 years. We will study the effects of these 2 treatments over 6 weeks and at 6 months. Subject to further funding, the Study will also look at whether these 6 weeks of treatment are effective 1 year and 2 years later.

Intervention Type

Drug

Phase

Phase IV

Drug/device/biological/vaccine name(s)

Depo-medrone

Primary outcome(s)

Symptom severity and limitations in hand function as assessed by the Boston CTS questionnaire; Timepoint(s): 6 weeks, 6 months, 12 months and 24 months post-randomisation.

Key secondary outcome(s)

Not provided at time of registration

Completion date

31/12/2018

Eligibility

Key inclusion criteria

1. Male or female aged 18 years or over
2. A clinical diagnosis of unilateral or bilateral CTS as made by a GP or trained clinician according to the diagnostic criteria
3. Mild (e.g. intermittent paraesthesia) or moderate (e.g. constant paraesthesia, reversible numbness and / or pain) severity CTS of idiopathic nature
4. Symptom duration of episode of at least 6 weeks
5. Written informed consent provided by the patient, prior to any trial specific procedures

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Steroid injection or night splints for CTS in the affected wrist within preceding 6 months
2. Any previous surgery on the affected wrist
3. Severe CTS exhibiting constant numbness or pain, constant sensory loss, severe thenar muscle atrophy or symptom severity which requires the patient to be referred for a surgical opinion
4. Clinical suspicion of local or systemic sepsis or infection
5. Current or previous infection of the affected wrist
6. Trauma to the affected hand requiring surgery or immobilisation in the previous 12 months
7. Unable to tolerate the study interventions
8. Unable to understand and complete self report questionnaires written in English
9. Intercurrent illness including, but not limited to: poorly controlled thyroid disease, poorly controlled diabetes mellitus, vibration-induced neuropathy, inflammatory joint disease, suspected complex neurological conditions, any other severe medical illness which in the opinion of the local Principal Investigator (or other authorised clinical delegate) precludes trial participation
10. Pregnant or lactating females
11. Receiving anticoagulants
12. Any history of hypersensitivity to DepoMedrone or any of its excipients (refer to the Summary of Product Characteristics (SPC))
13. Allergy to any of the splint materials (refer to manufacturers specification)
14. Known abuse of drugs or alcohol
15. Involved in ongoing litigation cases for their condition

Date of first enrolment

17/04/2014

Date of final enrolment

01/09/2017

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Keele University

Newcastle-Under-Lyme

United Kingdom

ST5 5BG

Sponsor information

Organisation

University of Keele (UK)

ROR

<https://ror.org/00340yn33>

Funder(s)

Funder type

Charity

Funder Name

Arthritis Research UK (UK)

Alternative Name(s)

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon request from Dr Linda Chesterton, l.s.chesterton@keele.ac.uk

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	20/10/2018		Yes	No
Protocol article	protocol	06/10/2016		Yes	No
HRA research summary			28/06/2023	No	No